Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.

Cancer medicine - 1 Feb 2022

Zhang Wenjing, Shi Fuyan, Kong Yujia, Li Yuting, Sheng Chao, Wang Suzhen, Wang Qinghua

Abstract excerpt

PURPOSE: Protein tyrosine phosphatase receptor type T (PTPRT), which is a well-known phosphatase and mutates frequently in melanoma and non-small cell lung cancer (NSCLC). Our research aims to elucidate its mutation association with immune checkpoint inhibitors (ICI) efficacy. METHODS: We integrated whole-exome sequencing (WES)-based somatic mutation profiles and clinical characteristics of 631 melanoma samples...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Melanoma

Share to Mutation

Share to Phosphoric Monoester Hydrolases

Share to Receptor-Like Protein Tyrosine Phosphatases, Class 2

Source

Open in PubMed Open full text

Identifiers

PMID: 34862763
DOI: 10.1002/cam4.4472
PMCID: PMC8817076

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.PMID 34862763Read ↗

Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.Semantic proximity Read ↗

PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.Semantic proximity Read ↗

Association of EYS mutations with immune checkpoint inhibitor outcome and response in melanoma and non-small cell lung cancerSemantic proximity Read ↗

RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.Semantic proximity Read ↗

Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations.Semantic proximity Read ↗

Immune checkpoint PTPN2 predicts prognosis and immunotherapy response in human cancersSemantic proximity Read ↗

PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer.Semantic proximity Read ↗

An integrative prognostic and immune analysis of PTPRD in cancerSemantic proximity Read ↗

Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.Semantic proximity Read ↗

The immune response-related genomic alterations in patients with malignant melanoma.Semantic proximity Read ↗

PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.Semantic proximity Read ↗

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.